Outcomes , such as range of motion , recurrence , and clinical success , were frequently defined , however many different definitions were used .
This systematic review summarizes the outcome reporting st and ards in Dupuytren ’s disease treatment research .
Collagenase clostridium histolyticum in patients with Dupuytren’s contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes
In POINT X , a study design ed to reflect clinical practice and patient treatment choices , 254 European patients received  open-label collagenase  for Dupuytren ’s contracture . The most severely affected joint was treated first in 74 % of patients . In total , 52 % , 41 % , 7 % , and 1 % of patients selected the little , ring , middle , and index finger , respectively ; 79 % had one or two joints treated . Only 9 % of patients ( n = 24 ) received 4 or 5 injections . The mean improvement in total passive extension deficit ( TPED ) was 34 ° on day 1 , improving further by day 7 to 42 ° . This secondary improvement was maintained by day 90 and month 6 . The mean number of injections/joint was 1.2 for the metacarpophalangeal joint and 1.25 for the proximal interphalangeal joint . Median time to recovery was 4 days ; the mean improvement in h and function was clinical ly relevant as measured by the Unité Rhumatologique des Affections de la Main ( URAM ) score . In total , 87 % and 86 % of patients and physicians , respectively , were very satisfied or satisfied with treatment at month 6 , although correlation between TPED and patient satisfaction was weak ( Spearman −0.18 , 95 % CI −0.32 to  −0.06 ) . Collagenase  was well tolerated , with 10 ( 3.9 % ) patients experiencing severe adverse events . As a real-world study , the POINT X findings can be generalized to the at-large population
Outcomes , such as range of motion , recurrence , and clinical success , were frequently defined , however many different definitions were used .
This systematic review summarizes the outcome reporting st and ards in Dupuytren ’s disease treatment research .